2024 FUTURES Responding to AAV Based Treatment Challenges

A moderated panel discussion focusing on the potential challenges and complications of AAV therapy and the clinical strategies to make dosing AAV more successful.

Michael Kelly, PhD

Chief Scientific Advisor


Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

Carsten Bönnemann, MD

Chief, Neuromuscular and Neurogenetic Disorders of Childhood Section National Institute of Neurological Disorders and Stroke/NIH

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

Robyn van Poelgeest, MD, PhD


Sharif Tabebordbar, PhD

Co-Founder and Chief Scientific Officer

Kate Therapeutics

Related Resources

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.